

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

IL18RAP RABBIT PAB

货号: S221218

产品全名: IL18RAP 兔多抗

基因符号 ACPL; CD218b; IL-1R7; IL18RB; CDw218b; IL-1R-7; IL-18RACP; IL-18RACPL; IL-18Rbeta; IL-18R-beta

UNIPROT ID: O95256 (Gene Accession - NP_003844)

背景: The protein encoded by this gene is an accessory subunit of the heterodimeric receptor for interleukin 18 (IL18), a proinflammatory cytokine involved in inducing cell-mediated immunity. This protein enhances the IL18-binding activity of the IL18 receptor and plays a role in signaling by IL18. Mutations in this gene are associated with Crohn's disease and inflammatory bowel disease, and susceptibility to celiac disease and leprosy. Alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known.

抗原: Synthetic peptide of human IL18RAP

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 221218(IL18RAP Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with the synthetic peptide and then with 221218(Anti-IL18RAP Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human liver cancer tissue using 221218(Anti-IL18RAP Antibody) at a dilution of 1/50.



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with synthetic peptide and then with D262724(Anti-IL18RAP Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010